To the editor:
The epidermal growth factor receptor (EGFR) inhibitor erlotinib has demonstrated significant EGFR-independent activity against acute myeloid leukemia (AML) cell lines and primary AML blasts in preclinical studies, however these findings have not been reproduced in clinical trials 1, 2 . Combining erlotinib with other antineoplastic agents has been proposed as a strategy for improving the clinical activity of erlotinib in AML 1, 2 . With the goal of identifying erlotinib combination candidates, we screened erlotinib against several chemical libraries in the erlotinib-insensitive AML cell lines TEX and OCI-AML2, identifying the poly(ADP-ribose) glycohydrolase (PARG) inhibitor ethacridine lactate as the top synergistic hit common to both cell lines. The erlotinib-ethacridine combination synergized to induce lethal levels of reactive oxygen species (ROS), resulting from erlotinib-mediated potentiation of intracellular ethacridine accumulation. Thus, we have identified that erlotinib promotes the accumulation of select drugs, thereby leading to synergism. In addition, the potential anti-AML activity of PARG inhibitors warrants further study. Erlotinib has well-documented preclinical activity against AML cells, where it induces differentiation 3 , cell cycle arrest [3] [4] [5] , and apoptosis 3, 6 , yet EGFR expression in these cells is absent 3, 7 . To evaluate erlotinib sensitivity in the AML cell lines TEX and OCI-AML2, we subjected these cells to treatment with increasing concentrations of erlotinib for 72 hours, and subsequently measured relative growth and viability using the sulforhodamine-B (SRB) assay.
The average erlotinib IC 50 s were 8.99 μ M and 15.61 μ M in TEX and OCI-AML2, respectively ( Figure S1 ). These erlotinib IC 50 values were significantly higher than clinically achievable concentrations 8 and far greater than the IC 50 of the EGFR-mutant NSCLC cell line HCC827 determined using the Cell Titer Fluor growth and viability assay ( Figure S1 ).
Given the relative insensitivity of TEX and OCI-AML2 cells to erlotinib, we sought to identify compounds that sensitize these cells to erlotinib-induced killing. We therefore screened Table S1 for patient characteristics). In contrast, the erlotinib-ethacridine combination was not synergistic in either of the normal hematopoietic cell samples derived from healthy donors of GCSF-mobilized peripheral blood stem cells ( Figure 2B, Figure S2 ). Evaluation of the erlotinib-ethacridine combination in an in vivo model of AML where SCID mice were subcutaneously injected with OCI-AML2 cells demonstrated reduced tumor growth (****P < 0.0001) ( Figure 2C) , with minimal change in bodyweight ( Figure 2D ).
Having validated this synergistic combination in preclinical AML models, we sought to characterize the mechanism responsible for its lethality. We quantified intracellular reactive oxygen species (ROS) production in TEX and OCI-AML2 cells following a 24-hour incubation with erlotinib, ethacridine, or both drugs in combination. ROS was measured using carboxy-H 2 DCFDA (FITC) staining on flow cytometry, and the absence of ethacridine autofluorescence in this channel was confirmed ( Figure S3 ). We observed a striking increase in ROS production:
up to a 2-fold increase in TEX and a 4-fold increase in OCI-AML2 cells, respectively ( Figure   3A ). ROS induction appeared functionally important for combination-induced synergistic cytotoxicity, as pre-treatment with the antioxidant α -tocopherol significantly increased viability as shown by Annexin V and PI staining following a 48-hour treatment with the erlotinibethacridine combination ( Figure 3B) . Interestingly, the source of ROS was likely not mitochondrial in origin, as MitoSOX staining was not increased following combination erlotinibethacridine treatment of TEX and OCI-AML2 cells ( Figure S4 ). Figure 3C ). Thus, PARG inhibition is a possible target of ethacridine explaining its synergy with erlotinib, and further evaluation of this target in AML cells is warranted.
We next sought to identify the target(s) of erlotinib responsible for its synergy with ethacridine. Given that several kinase targets-such as SRC family kinases, BTK, SYK, and Table S2 for screen data). Erlotinib was the second most synergistic hit, which served as further validation for our initial combination screen. Interestingly, 4 of the 5 top synergistic hits (GW583340, erlotinib, GW2974, and WHI-P 154) were reported EGFR inhibitors. Furthermore, the clinically approved EGFR inhibitors gefitinib and lapatinib were also identified as synergistic hits ( Table S2 ).
The observed synergy between ethacridine and multiple EGFR inhibitors prompted us to investigate whether erlotinib might inhibit EGFR to synergize with ethacridine in TEX and OCI- OCI-AML2
